Insights from SciBase Holding AB's 2026 Annual General Meeting

On May 19, 2026, SciBase Holding AB, a pioneering medical technology firm based in Sweden, conducted its annual general meeting (AGM). The meeting highlighted significant decisions and outcomes that shape the company's future and reaffirm its commitment to improving skin health management. Below, we delve into the crucial resolutions adopted during the AGM.

Financial Statements Adoption

The AGM approved the profit and loss statement, along with the balance sheet, for the fiscal year ending 2025. This endorsement reflects the company's performance metrics and financial health. Subsequently, shareholders learned that no dividend would be distributed for the 2025 financial year, with the year's results being allocated for future growth.

Discharge of Liability

As part of the proceedings, the shareholders granted discharge from liability to the board members and CEO for their actions during the previous fiscal year. This action signifies confidence in the leadership and their strategic decisions over the past year.

Board Composition and Remuneration

The meeting resolved that the board would comprise four ordinary members with no deputy members. The shareholders also approved the remuneration structure for board members, specifying SEK 415,000 for the chair and SEK 150,000 for other ordinary board members who aren’t employed by larger shareholders of the company.

For the upcoming term, the AGM re-elected Jesper Høiland, Robert Molander, Diana Ferro, and Anna Eriksrud as board members, with Høiland continuing as the board's chairman. The firm Öhrlings PricewaterhouseCoopers AB was elected as the auditor, with Magnus Lagerberg appointed as the lead auditor.

Amendments to Articles of Association

One notable change ratified during the AGM was the amendment to the articles of association, which introduced a reverse share split. This split saw every one hundred existing shares being consolidated into one new share, advancing the quota value from SEK 0.05 to SEK 5.00. Such corporate actions are seen as a strategic maneuver to enhance share value.

Stock Option Program Introduction

The AGM also sanctioned the implementation of a stock option program. This initiative involves a directed issue of warrants to fulfill the company's commitments under the stock option program. This measure is poised to motivate employees and align their interests with those of shareholders.

Board's Authorization to Raise Capital

Further, shareholders authorized the board of directors to increase share capital through the issuance of new shares, warrants, or convertible debentures. Importantly, these issuances will not exceed a 20 percent dilution of the share capital and votes in the company post-issue. This measure aims to provide the company with flexibility in funding future projects.

Conclusion

This year's AGM underscores the strategic vision of SciBase Holding AB as it continues to innovate in dermatology. The company leverages its 20 years of research at the Karolinska Institute to provide cutting-edge diagnostic solutions through its flagship product, Nevisense. As SciBase moves forward, the approved resolutions set the stage for further growth and development in enhancing skin health management.

For detailed profiles of board members and their qualifications, interested parties can refer to the company’s website. For more updates and press releases, stakeholders are encouraged to visit the investor relations section as SciBase continues to advance its mission in early skin cancer detection and prevention.